Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 17/20 | 0.56 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.51 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6970484 | 0.97 | AVPR2 (0.55) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6972071 | 0.97 | AVPR2 (0.54) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6966950 | 0.95 | AVPR2 (0.52) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6970694 | 0.95 | AVPR2 (0.52) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6967669 | 0.93 | AVPR2 (0.56) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6959290 | 0.93 | AVPR2 (0.52) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6965665 | 0.93 | AVPR2 (0.53) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6972761 | 0.92 | AVPR2 (0.52) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6958364 | 0.92 | AVPR2 (0.52) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6971132 | 0.92 | AVPR2 (0.54) | AVPR2AVPR1AOXTRAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006142-A1 | Ocular tension depressor | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | claimed |
| EP-1280523-A2 | USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF HIGH OCULAR TENSION AND GLAUCOMA | Sucampo AG (CH) | 2003-02-05 | — | — | EP | claimed |
| EP-0620216-B1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-01-08 | — | — | EP | claimed |
| WO-2001082913-A2 | USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF HIGH OCULAR TENSION AND GLAUCOMA | SUCAMPO AG (CH) | 2001-11-08 | — | — | WO | claimed |
| US-5521170-A | VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-28 | — | — | US | claimed |
| EP-0620216-A1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | claimed |
| US-20040006142-A1 | Ocular tension depressor | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1280523-A2 | USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF HIGH OCULAR TENSION AND GLAUCOMA | Sucampo AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| EP-0620216-B1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001082913-A2 | USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF HIGH OCULAR TENSION AND GLAUCOMA | SUCAMPO AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| US-6268359-B1 | Preventives or remedies for vision disorders | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| EP-1050308-A1 | PREVENTIVES OR REMEDIES FOR VISION DISORDERS | Senju Pharmaceutical Co., Ltd. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-1996033723-A2 | USE OF BENZAMIDE DERIVATIVES FOR TREATING AND/OR PREVENTING MENIERE'S SYNDROME AND MOTION SICKNESS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-31 | — | — | WO | disclosed |
| US-5521170-A | VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| EP-0620216-A1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006142-A1 | Ocular tension depressor | TPH2, TPH1, ALDH1A2 | AVPR2 591/4885AVPR1A 1158/4885OXTR 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.